Name: Name:Refametinib
Brand: AABLOCKS
SKU: AA00GR9W
Rating: 90 (10 reviews)

Technical Information

Catalog Number: AA00GR9W

Chemical Name: Refametinib

CAS Number: 923032-37-5

Molecular Formula: C19H20F3IN2O5S

Molecular Weight: 572.3372

MDL Number: MFCD18633256

SMILES: OC[C@H](CC1(CC1)S(=O)(=O)Nc1c(OC)cc(c(c1Nc1ccc(cc1F)I)F)F)O

Properties

Complexity: 711

Covalently-Bonded Unit Count: 1

Defined Atom Stereocenter Count: 1

Defined Bond Stereocenter Count: 0

Formal Charge: 0

Heavy Atom Count: 31

Hydrogen Bond Acceptor Count: 10

Hydrogen Bond Donor Count: 4

Isotope Atom Count: 0

Rotatable Bond Count: 9

Undefined Atom Stereocenter Count: 0

Undefined Bond Stereocenter Count: 0

XLogP3: 2.8

Literature fold

Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.

Journal: Bioorganic & medicinal chemistry letters20130801

Title: Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20130301

Title: MEK and the inhibitors: from bench to bedside.

Journal: Journal of hematology & oncology20130101

Title: Induction of sodium/iodide symporter (NIS) expression and radioiodine uptake in non-thyroid cancer cells.

Journal: PloS one20120101

Title: Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice.

Journal: Science (New York, N.Y.)20110415

Title: BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus.

Journal: International journal of cancer20101215

Title: Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts.

Journal: BMC cancer20100101

Title: RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.

Journal: Cancer research20090901

Title: Iverson C, et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res. 2009 Sep 1;69(17):6839-47.

923032-37-5 | Refametinib